OpenNashEarnings

Biotechnology · Nasdaq: MRNA

Moderna earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 12 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Moderna won FDA approval for mFLUSIVA, its fifth approved product and the first mRNA flu vaccine, and reported positive Phase 3 intismeran melanoma results with Merck.

Moderna added its fifth approved product when the FDA approved mFLUSIVA, its mRNA seasonal flu vaccine, for adults 50 and older. The U.S. launch is limited this season because approval came after the annual contracting cycle. Demand for updated COVID vaccines was strong, driven by international government partnerships and growing U.S. uptake of mNEXSPIKE. Intismeran, developed with Merck, also showed a 42% reduction in the risk of recurrence or death in melanoma when added to KEYTRUDA.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$1.3B+29.2% y/yQ3 2026
Q4 2024: $966.0M (worked out from the annual figure)Q4 ’24$966.0MQ1 2025: $108.0MQ1 ’25$108.0MQ2 2025: $142.0MQ2 ’25$142.0MQ3 2025: $1.0BQ3 ’25$1.0BQ4 2025: $678.0M (worked out from the annual figure)Q4 ’25$678.0MQ1 2026: $389.0MQ1 ’26$389.0MQ2 2026: $145.0MQ2 ’26$145.0MQ3 2026: $1.3BQ3 ’26$1.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$966.0M *
Q1 2025$108.0M
Q2 2025$142.0M
Q3 2025$1.0B
Q4 2025$678.0M *
Q1 2026$389.0M
Q2 2026$145.0M
Q3 2026$1.3B
Diluted EPS (GAAP)$0.38Q3 2026
Q1 2025: -$2.52Q1 ’25-$2.52Q2 2025: -$2.13Q2 ’25-$2.13Q3 2025: -$0.51Q3 ’25-$0.51Q1 2026: -$3.40Q1 ’26-$3.40Q2 2026: -$1.97Q2 ’26-$1.97Q3 2026: $0.38Q3 ’26$0.38
Data
Q1 2025-$2.52
Q2 2025-$2.13
Q3 2025-$0.51
Q1 2026-$3.40
Q2 2026-$1.97
Q3 2026$0.38

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin9.9%+35.5 pts y/yQ3 2026
Q4 2024: -129.0%Q4 ’24-129.0%Q1 2025: -972.2%Q1 ’25-972.2%Q2 2025: -638.7%Q2 ’25-638.7%Q3 2025: -25.6%Q3 ’25-25.6%Q4 2025: -126.4%Q4 ’25-126.4%Q1 2026: -356.8%Q1 ’26-356.8%Q2 2026: -562.1%Q2 ’26-562.1%Q3 2026: 9.9%Q3 ’269.9%
Data
Q4 2024-129.0%
Q1 2025-972.2%
Q2 2025-638.7%
Q3 2025-25.6%
Q4 2025-126.4%
Q1 2026-356.8%
Q2 2026-562.1%
Q3 20269.9%
Free cash flow-$1.6B−82.5% y/yQ3 2026
Q4 2024: $303.0MQ4 ’24$303.0MQ1 2025: -$1.2BQ1 ’25-$1.2BQ2 2025: -$922.0MQ2 ’25-$922.0MQ3 2025: -$880.0MQ3 ’25-$880.0MQ4 2025: $891.0MQ4 ’25$891.0MQ1 2026: -$692.0MQ1 ’26-$692.0MQ2 2026: -$563.0MQ2 ’26-$563.0MQ3 2026: -$1.6BQ3 ’26-$1.6B
Data
Q4 2024$303.0M
Q1 2025-$1.2B
Q2 2025-$922.0M
Q3 2025-$880.0M
Q4 2025$891.0M
Q1 2026-$692.0M
Q2 2026-$563.0M
Q3 2026-$1.6B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$966.0Md$108.0M$142.0M$1.0B$678.0Md$389.0M$145.0M$1.3B
Operating income-$1.2Bd-$1.1B-$907.0M-$260.0M-$857.0Md-$1.4B-$815.0M$130.0M
Operating margin-129.0%-972.2%-638.7%-25.6%-126.4%-356.8%-562.1%9.9%
Net income-$1.1Bd-$971.0M-$825.0M-$200.0M-$826.0Md-$1.3B-$782.0M$162.0M
Diluted EPS—-$2.52-$2.13-$0.51—-$3.40-$1.97$0.38
Operating cash flow$825.0Md-$1.0B-$919.0Md-$847.0Md$930.0Md-$630.0M-$526.0Md-$1.6Bd
Capital expenditure$522.0Md$117.0M$3.0Md$33.0Md$39.0Md$62.0M$37.0Md$47.0Md
Free cash flow$303.0M-$1.2B-$922.0M-$880.0M$891.0M-$692.0M-$563.0M-$1.6B
R&D expense$1.1Bd$856.0M$700.0M$801.0M$775.0Md$649.0M$651.0M$583.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings